BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Camilleri M. Toward an effective peripheral visceral analgesic: responding to the national opioid crisis. Am J Physiol Gastrointest Liver Physiol 2018;314:G637-46. [PMID: 29470146 DOI: 10.1152/ajpgi.00013.2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Brierley SM, Grundy L, Castro J, Harrington AM, Hannig G, Camilleri M. Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain. Trends Pharmacol Sci 2021:S0165-6147(21)00217-0. [PMID: 34865885 DOI: 10.1016/j.tips.2021.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ya K, Tangamornsuksan W, Scholfield CN, Methaneethorn J, Lohitnavy M. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review. Asian J Psychiatr 2019;43:73-82. [PMID: 31100603 DOI: 10.1016/j.ajp.2019.05.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
3 Jiménez-Vargas NN, Yu Y, Jensen DD, Bok DD, Wisdom M, Latorre R, Lopez C, Jaramillo-Polanco JO, Degro C, Guzman-Rodriguez M, Tsang Q, Snow Z, Schmidt BL, Reed DE, Lomax AE, Margolis KG, Stein C, Bunnett NW, Vanner SJ. Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects. Gut 2021:gutjnl-2021-324070. [PMID: 33785555 DOI: 10.1136/gutjnl-2021-324070] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
4 Camilleri M. Irritable Bowel Syndrome: Straightening the road from the Rome criteria. Neurogastroenterol Motil 2020;32:e13957. [PMID: 32808411 DOI: 10.1111/nmo.13957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Uranga JA, Vera G, Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol 2018;157:134-47. [PMID: 30076849 DOI: 10.1016/j.bcp.2018.07.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
6 Camilleri M. Towards a new era with safer µ-opiate receptor analgesia. Gut 2022;71:1-2. [PMID: 33875448 DOI: 10.1136/gutjnl-2021-324618] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Farmer AD. Non‐inasive vagus nerve stimulation—Hope or hype? Neurogastroenterology & Motility 2020;32. [DOI: 10.1111/nmo.13822] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Camilleri M. What's in the pipeline for lower functional gastrointestinal disorders in the next 5 years? Am J Physiol Gastrointest Liver Physiol 2019;317:G640-50. [PMID: 31460793 DOI: 10.1152/ajpgi.00205.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Magni G, Ceruti S. The role of adenosine and P2Y receptors expressed by multiple cell types in pain transmission. Brain Res Bull 2019;151:132-43. [PMID: 30797817 DOI: 10.1016/j.brainresbull.2019.02.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018;93:1858-1872. [PMID: 30522596 DOI: 10.1016/j.mayocp.2018.04.032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
11 Farmer AD, Albusoda A, Amarasinghe G, Ruffle JK, Fitzke HE, Idrees R, Fried R, Brock C, Aziz Q. Transcutaneous vagus nerve stimulation prevents the development of, and reverses, established oesophageal pain hypersensitivity. Aliment Pharmacol Ther 2020;52:988-96. [PMID: 32767824 DOI: 10.1111/apt.15869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]